Molecular Markers in Treatment in Endometrial Cancer (MoMaTEC)
Prospective Study of Endometrial Cancer Treatment in Relation to Molecular Markers in Curettage Specimens.
Sponsor: Helse-Bergen HF
This observational or N/A phase trial investigates Endometrial Neoplasms and Neoplasm Metastasis and is currently ongoing. Helse-Bergen HF leads this study, which shows 11 recorded versions since 2001 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Dec 2021 — Jul 2024 [monthly]
Unknown Status
-
Jan 2021 — Dec 2021 [monthly]
Unknown Status
-
Nov 2020 — Jan 2021 [monthly]
Unknown Status
▶ Show 6 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Unknown Status
-
May 2018 — Jun 2018 [monthly]
Unknown Status
-
Apr 2018 — May 2018 [monthly]
Unknown Status
Phase: NA → None
-
Feb 2018 — Apr 2018 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
-
Aug 2017 — Feb 2018 [monthly]
Recruiting NA
-
Jan 2017 — Aug 2017 [monthly]
Recruiting NA
First recorded
Apr 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Helse-Bergen HF
- Norwegian Cancer Society
- University of Bergen
For direct contact, visit the study record on ClinicalTrials.gov .